Post-Hoc: China deals are pharma’s new tax inversions

June 29, 2026 09:00 AM EDT DealsChina Post-Hoc: Chi­na deals are phar­ma’s new tax in­ver­sions Drew Armstrong Executive Editor About a decade ago, when I had just start­ed cov­er­ing phar­ma, one of the biggest sto­ries was tax in­ver­sions. For those who don’t re­mem­ber, tax … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER